Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?

Lung cancer patients ≥75 years represent nearly 40% of all lung cancer patients and continue to increase. If elderly patients have a good performance status and adequate organ function, they can be treated the same as non-elderly patients. However, few comparative studies limited to elderly patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers (Basel)
Hlavní autoři: Takigawa, Nagio, Ochi, Nobuaki, Nakagawa, Nozomu, Nagasaki, Yasunari, Taoka, Masataka, Ichiyama, Naruhiko, Mimura, Ayaka, Nakanishi, Hidekazu, Kohara, Hiroyuki, Yamane, Hiromichi
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2020
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7409336/
https://ncbi.nlm.nih.gov/pubmed/32708291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12071995
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky